Fortrea Swings to Q3 Profit, Raises Full-Year Guidance Midpoints
FTRE has more than doubled off its 52-week low of $8.55 on elevated volume (2.3× avg).
Summary
Fortrea posted Q3 revenue of $691.5 million, down from $701.3 million a year ago, but flipped to a $0.6 million GAAP profit from a $15.9 million loss. Adjusted EBITDA rose to $58.0 million from $50.7 million and adjusted diluted EPS doubled to $0.28 from $0.12. Book-to-bill came in at 1.12x for the quarter and the trailing 12 months, and the company generated $52.5 million of free cash flow. The company cut backlog by $558 million to $7,316 million to reflect estimated scope and inactive trials, saying the adjustment has no impact on historical results or 2026 guidance. It raised the midpoints of full-year revenue ($2,665-$2,690 million) and adjusted EBITDA ($210-$218 million) guidance while narrowing both ranges. The stock is trading near its 52-week high of $26.16 ahead of the 8:00 am ET call, where management will face questions on the backlog write-down and whether bookings convert to revenue growth.
At the time of this announcement, FTRE was trading at $25.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $8.55 to $26.16. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.